Breakthrough Findings from the Latest Phase 3 Trial
The landscape of human immunodeficiency virus type 1 (HIV-1) management continues to evolve with innovative treatment strategies aimed at simplifying regimens while maintaining long-term viral suppression. A pivotal advancement comes from a recently published phase 3 trial in The Lancet, demonstrating the efficacy of switching virologically suppressed patients to a fixed-dose combination of doravirine and islatravir. This open-label study provides compelling evidence for a novel two-drug regimen that could offer a non-integrase strand transfer inhibitor (INSTI)-based alternative in HIV switch therapies.
Virologically suppressed patients—those with HIV-1 RNA levels below 50 copies per milliliter (c/mL)—represent a significant portion of the treated population. Switch therapies allow clinicians to optimize treatment by reducing pill burden, minimizing side effects, or addressing resistance concerns without compromising control. In Europe, where approximately 778,000 people live with HIV in the EU/EEA alone, such options are crucial amid challenges like late diagnoses affecting over half of cases.
Decoding Doravirine and Islatravir: Mechanisms and Development
Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI), works by binding to the reverse transcriptase enzyme of HIV-1, preventing the virus from replicating its genetic material into host DNA. Approved as part of Delstrigo (doravirine/lamivudine/tenofovir disoproxil) since 2018, it stands out for its high barrier to resistance and minimal drug interactions compared to older NNRTIs like efavirenz.
Islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor (NRTTI), represents a next-generation nucleoside analog. Unlike traditional nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir or emtricitabine, ISL inhibits the translocation step of reverse transcriptase, offering potent activity even against some resistant strains. Developed by Merck, the fixed-dose combination (FDC) of doravirine 100 mg and islatravir 0.25 mg in a single tablet simplifies once-daily dosing.
This pairing leverages complementary resistance profiles: DOR targets NNRTI mutations, while ISL addresses NRTI-related ones, potentially broadening utility in switch scenarios from INSTI-based regimens like bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy).
Trial Design: Rigorous Evaluation of Switch Efficacy
Conducted across 53 clinics in eight countries—including European sites in the UK and Switzerland—the trial (NCT05631093) enrolled 553 adults aged 18 and older who had maintained viral suppression (<50 HIV-1 RNA c/mL) on stable two- or three-drug oral antiretroviral therapy (ART) for at least three months. Participants were randomized 2:1 to switch to the DOR/ISL FDC or continue their baseline regimen, stratified by anchor class (INSTI, NNRTI, or protease inhibitor).
Key exclusion criteria included prior treatment failure, doravirine resistance mutations, or active hepatitis B. Median age was 51 years, with 60% assigned male at birth and diverse representation (45% Black/African American, 15% Hispanic/Latino). The primary endpoint was the proportion with HIV-1 RNA ≥50 c/mL at week 48 using the FDA snapshot algorithm (intent-to-treat exposed population).
Efficacy Outcomes: Non-Inferiority Confirmed
At week 48, virologic failure (HIV-1 RNA ≥50 c/mL) occurred in just 1.4% (5/366) of the DOR/ISL group versus 4.9% (9/185) continuing baseline ART. The adjusted difference was -3.6% (95% CI: -7.8% to -0.8%), with the upper confidence interval below the prespecified 4% non-inferiority margin, establishing robust efficacy.
- Virologic success rates highlight maintenance of suppression in over 98% on switch.
- No protocol-defined failures due to resistance emerged in the switch arm.
- Subgroup consistency across age, sex, race, and baseline regimen types.
These results align with prior phase 3 data on higher-dose ISL (0.75 mg), reinforcing the regimen's potential.
Safety Profile: Well-Tolerated with Manageable Events
Safety data were reassuring, with similar rates of any adverse events (79.5% vs. 83.8%) and serious adverse events (6.3% vs. 4.9%). Treatment-related adverse events were higher in the switch arm (12.0% vs. 4.9%), primarily mild-to-moderate like headache or nausea, but discontinuations due to adverse events were low (0.5% vs. 2.2%). No cases linked to CD4 or lymphocyte declines, addressing prior concerns with higher ISL doses.
| Event Type | DOR/ISL (%) | Baseline ART (%) |
|---|---|---|
| Treatment-Related AEs | 12.0 | 4.9 |
| Serious AEs | 6.3 | 4.9 |
| Discontinuation due to AE | 0.5 | 2.2 |
Context in European HIV Landscape
Europe faces a persistent HIV burden, with 24,164 new diagnoses in the EU/EEA in 2024 (rate 5.3/100,000), down slightly but marred by 54% late presentations. The European AIDS Clinical Society (EACS) guidelines version 13.0 emphasize switch strategies to two- or three-drug regimens for simplification, particularly avoiding INSTI weight gain or bone effects.
In countries like the UK and Germany, where trial sites operated, adoption could align with national programs. For instance, Switzerland's robust screening contrasts with higher-incidence Eastern Europe, where simplified regimens aid adherence.
ECDC HIV Surveillance Report 2025Comparisons to Current Switch Options
- INSTI-based: Biktarvy excels but linked to weight gain (3-5 kg/year in some).
- Two-drug: Dolutegravir/lamivudine effective but DTG neuropsychiatric risks.
- DOR/ISL advantage: Lighter profile, no tenofovir renal/bone issues, high resistance barrier.
Merck's NDA for suppressed patients targets FDA approval by April 2026, with EMA implications for Europe.
Implications for Clinical Practice in Europe
For European clinicians, this regimen promises flexibility for patients on long-term INSTIs seeking alternatives. In virologically suppressed individuals—over 90% of treated in Western Europe—switching could enhance quality of life via reduced pills and side effects. Cost-effectiveness analyses will be key, especially under national health systems like the NHS.
Stakeholder views from EACS conferences highlight enthusiasm for non-INSTI options amid resistance concerns.
Research Contributions from European Universities
Lead author Chloe Orkin from Queen Mary University of London underscores Europe's role in global trials. Sites at University College London and Swiss institutions contributed diverse data, fostering collaborations. Such studies exemplify how university-led research drives innovation.Explore research jobs in clinical trials across Europe.
Career Opportunities in HIV Research
The trial's success signals growing demand for experts in virology, pharmacology, and epidemiology. European universities like Ghent University and Vrije Universiteit Brussel seek PhD candidates and postdocs for HIV cure research.Clinical research jobs abound, from trial coordinators to data analysts. Platforms like AcademicJobs higher ed jobs list roles in faculty and postdoc positions.
Professionals can advance via career advice on academic CVs, positioning themselves in this dynamic field.
Future Outlook and Regulatory Pathways
Week 96 data pending, but early signals support long-term use. Merck plans congress presentations and regulatory filings. In Europe, EMA review could enable 2027 access, complementing long-acting injectables like cabotegravir/rilpivirine.
Challenges include monitoring lymphopenia risks and real-world adherence. Optimism prevails for simplified, effective HIV care.
Actionable Insights for Researchers and Clinicians
- Monitor EMA updates for DOR/ISL approval.
- Consider switches for INSTI-intolerant patients post-suppression.
- Engage in trials via university networks for career growth.
- Visit Rate My Professor for insights on HIV faculty.
For job seekers, university jobs in Europe offer entry to impactful research. Explore higher ed career advice and higher ed jobs today.